The Filing Desk

Curis vs Taysha Gene Therapies

Curis CRIS · Taysha Gene Therapies TSHA · Biotechnology

Taysha Gene Therapies reported revenue of $10 million in fiscal 2025, about the same as Curis' $9 million in fiscal 2025. Curis' revenue fell 13.4% in its latest year, and Taysha Gene Therapies' grew 17.3%. Curis had an operating margin of -60.5%, against -1130.7% at Taysha Gene Therapies.

Side by side

CurisTaysha Gene Therapies
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$9M$10M
Revenue growth−13.4%17.3%
Revenue growth a year, last 5 years−2.7%—
Gross margin——
Operating margin−60.5%−1,130.7%
Net margin−80.3%−1,115.3%
Free cash flow—−$94M
Free cash flow margin—−960.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count108.7%27.8%
Last close$0.47$3.77
P/E at the last close——
Insider trades, last 12 monthsbought $5,500, sold $0sold $6.7 million
Piotroski F-score3 of 84 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CurisTaysha Gene Therapies
Operating margin
Percent of revenue
CurisTaysha Gene Therapies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CurisTaysha Gene Therapies

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Curis and Taysha Gene Therapies pages.